Brimonidine 0.1% Versus Brinzolamide 1% as Adjunctive Therapy to Latanoprost 0.005%

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00440141

Enrollment

Registered

2007-02-26

Start date

2006-07-31

Completion date

2007-03-31

Last updated

2008-01-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma, Ocular Hypertension

Brief summary

Patients with glaucoma or ocular hypertension currently being treated with latanoprost 0.005%, and in need of additional IOP lowering will be randomized to receive either brimonidine 0.1% or brinzolamide 1% three-times daily as adjunctive therapy to latanoprost 0.005%

Interventions

DRUGlatanoprost 0.005% eye drops and brinzolamide 1.0% eye drops

latanoprost 0.005% 1 drop nightly for 3 months AND brinzolamide 1.0% 1% three-times daily for 3 months

DRUGlatanoprost 0.005% eye drops and brimonidine 0.1% eye drops

latanoprost 0.005%, 1 drop nightly for 3 months and brimonidine 0.1% three-times daily for 3 months

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Glaucoma or ocular hypertension in both eyes * Currently being treated with latanoprost 0.005% QD * IOP greater than or equal to 18mm Hg on latanoprost 0.005% * Best-corrected VA of 20/200 or better in each eye * Visual field within 6 months of study entry

Exclusion criteria

* Secondary glaucoma * Active intraocular inflammation or macular edema * Intraocular surgery or laser surgery within the past 3 months

Design outcomes

Primary

Measure	Time frame
IOP	Month 3

Secondary

Measure	Time frame
Tolerability	Month 3

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026